FindDrugs.org

MEDVi Weight Loss / GLP-1 Review

Weight Loss / GLP-1 · Reviewed Sep 23, 2026

5.36/10
MEDVi operator trust5.50/10See the full MEDVi brand review
Clinician accessFastest startCash-pay

Our verdict

MEDVi is a fast-growing cash-pay telehealth marketing brand that sells compounded semaglutide and tirzepatide at transparent, published prices, with a quick async start across 49 states and a LegitScript-certified, NABP-accredited compounding partner in Belmar. What holds it back is where the substance sits: MEDVi owns no pharmacy, employs no physicians and holds no drug licenses, and it carries real integrity flags - a February 2026 FDA warning letter for misbranding, reporting that AI-generated doctor personas, testimonials and reviews appeared in affiliate ads (which MEDVi says it required an affiliate to take down), and a data breach at its infrastructure partner OpenLoop that OpenLoop's own notice and the federal HHS breach portal put at roughly 716,000 individuals (a hacker's claim of 1.6 million records is unverified). It suits price-sensitive shoppers who want speed and are comfortable with a fully outsourced, questionnaire-based model.

Price

from $279/mo · 3 plans

Visit MEDVi

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

Key takeaways

  • Pricing is not verifiable from a source we can use: MEDVi publishes no price we can retrieve, its site is refused on terms so we do not render it, and the figures that circulate are affiliate-sourced and withdrawn.
  • Coverage and shipping terms are not verifiable from a source we can use: a specific state count and a free-shipping claim were withdrawn, and medvi.org is refused on terms so we cannot check what it publishes.
  • Operates as a marketing and care-coordination layer; care via OpenLoop/CareValidate, compounding via Belmar
  • February 20, 2026 FDA warning letter (#721455) for misbranding, part of an industry-wide wave of 30+ letters
  • Reported AI-generated fake ads, reviews and doctor testimonials (MEDVi attributes them to an affiliate); ~716K-individual data breach at partner OpenLoop (Jan 2026; HHS OCR portal)
  • Month-to-month; the cancellation window and refund conditions are not verifiable from a source we can use — they were withdrawn as affiliate-only sourcing, and medvi.org is refused on terms so we cannot check what it publishes. 28-day billing means ~13 charges/year

What is MEDVi Weight Loss / GLP-1?

MEDVi is a direct-to-consumer telehealth brand focused on GLP-1 weight management. Rather than running its own clinical or pharmacy operations, it coordinates them through third parties: licensed US physicians review intake through networks such as OpenLoop and CareValidate, and medications are compounded by Belmar Pharma Solutions, which operates 503A pharmacies and a separate FDA-registered 503B outsourcing facility, with oral tablets reportedly filled by Triad Rx. It operates in 49 states (excluding North Dakota) on a cash-pay basis. The compounded medications MEDVi sells are not individually FDA-approved.

Treatment options

Prices as of Sep 23, 2026 — verify current on the brand's site.

Getting started with MEDVi

  1. Complete the online intake questionnaire (health history, weight-loss goals)
  2. A licensed partner-network physician reviews your intake, typically within 24-48 hours
  3. If eligible, your medication is compounded by the partner pharmacy and shipped free
  4. Start treatment within about a week; dose adjustments are included at the locked price
  5. Use 24/7 support and manage your month-to-month plan (cancel 72h before the next billing date)

Methodology scorecard

Scored on Sep 23, 2026 under methodology v6

5.36/10

Coverage: Checked against 6 recorded withdrawals. Marking matches the wording each withdrawal was recorded in, so the same claim stated differently is not marked.

  • Legitimacy & Accreditation
    Critical

    Evidence (as scored Sep 23, 2026): MEDVi says its compounded medications are prepared by Belmar Pharma Solutions. The accreditations Belmar lists on its own site could not be checked against the issuing registers, so they are company-attested rather than independently confirmed. A February 2026 FDA warning letter cited MEDVi for misbranding. — FDA warning letter — Medvi, Sep 23, 2026

  • Clinical Oversight & Safety
    Critical

    Evidence (as scored Sep 23, 2026): MEDVi names three partner pharmacies on its own GLP-1 page and requires an online medical evaluation before prescribing, but does not name the clinicians who conduct it. On the record: FDA warning letter #721455 (2026-02-20) citing misbranding violations. — FDA warning letter — Medvi, Aug 11, 2026

  • Sourcing Transparency & Legal Context
    High

    Evidence (as scored Sep 23, 2026): MEDVi requires an online medical evaluation and states that medication is included in the program; it does not publish BMI thresholds or a contraindication list on its GLP-1 page. — glp1.medvi.org, Jul 24, 2026

  • Data Privacy & Security
    Medium

    Evidence (as scored Sep 23, 2026): Large breach at the infrastructure partner (OpenLoop) that handles MEDVi patient data (~716,000 individuals per HHS OCR; 68,160 in Texas). — ocrportal.hhs.gov, May 11, 2026

  • Pricing Transparency & Value
    Critical

    Evidence (as scored Sep 23, 2026):

  • Quality-under-Growth
    Medium

    Evidence (as scored Sep 23, 2026): An FDA warning letter for misbranding was issued during a period of rapid scaling. Separately, a breach at its clinical-services partner OpenLoop affected 716,000 individuals on the HHS OCR register. — FDA warning letter — Medvi, Aug 11, 2026

  • Transparency & Disclosure
    Critical

    Evidence (as scored Sep 23, 2026): MEDVi does not disclose who compounds or who prescribes on its own pages, and does not publish a price before signup. On the record: FDA warning letter #721455 (2026-02-20) citing misbranding violations. — FDA warning letter — Medvi, Aug 11, 2026

  • Support & Care Model
    Supporting

    Evidence (as scored Sep 23, 2026): MEDVi requires an online medical evaluation before prescribing but does not publish BMI thresholds or the contraindications it screens for (MTC/MEN2, pancreatitis, pregnancy) on its own pages. The specific criteria previously reported came from a third-party review site. — glp1.medvi.org, Aug 10, 2026

  • Titration Autonomy
    High

    Evidence (as scored Sep 23, 2026): MEDVi requires an online medical evaluation and states that medication is included in the program; it does not publish BMI thresholds or a contraindication list on its GLP-1 page. — glp1.medvi.org, Aug 10, 2026

  • Weight-Management Care Model
    Medium

    Evidence (as scored Sep 23, 2026): MEDVi requires an online medical evaluation and states that medication is included in the program; it does not publish BMI thresholds or a contraindication list on its GLP-1 page. — glp1.medvi.org, Aug 10, 2026

  • Eligibility Screening
    High

    Evidence (as scored Sep 23, 2026): MEDVi requires an online medical evaluation and states that medication is included in the program; it does not publish BMI thresholds or a contraindication list on its GLP-1 page. — glp1.medvi.org, Jul 24, 2026

Pricing & cancellation

Visit MEDVi

All-in price

from $279/mo · 3 options

Cost structure
month-to-month (28-day billing cycles)
Insurance vs. cash
Cash-pay
Deal structure
Cancellation
Month-to-month; cancel 72h before next billing; standard cancellations non-refundable except medical disqualification
Forced subscription
Not required

Pros & cons

Pros

  • Transparent, publicly listed cash-pay pricing competitive vs brand-name GLP-1s
  • Compounding partner Belmar is LegitScript-certified and NABP-accredited (503A + 503B)
  • Fast access: async intake reviewed in 24-48h
  • Month-to-month with a stated 5-month money-back guarantee (75% refund)
  • High Trustpilot volume (~11,400 reviews) averaging ~4.4/5

Cons

  • Feb 20, 2026 FDA warning letter for misbranding
  • Reported AI-generated fake ads, reviews, and doctor testimonials (MEDVi attributes them to an affiliate marketer)
  • Clinical and pharmacy roles are not clearly disclosed
  • ~716K-individual data breach at infrastructure partner OpenLoop (Jan 2026; HHS OCR portal)
  • Pending class action alleging compounded oral tirzepatide lacks demonstrated efficacy

Safety

Talk to a licensed clinician

Eligibility follows standard guidelines - generally adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition - and intake screens for contraindications such as a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, pregnancy and pancreatitis. Screening is async and questionnaire-based, without mandatory lab work, and clinical oversight is entirely outsourced. Beyond the usual GLP-1 side effects, a notable concern is data safety: MEDVi routes patient data through OpenLoop, which disclosed a January 2026 data breach. OpenLoop's own notice and the federal HHS breach portal put it at roughly 716,000 individuals (68,160 of them Texas residents, per the Texas Attorney General), while a hacker's forum claim of 1.6 million records remains unverified. Treatment decisions and eligibility should be confirmed with a licensed clinician.

Common side effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Injection-site reactions

Who should not take it

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Pregnancy or breastfeeding
  • History of pancreatitis
  • Known hypersensitivity to GLP-1 receptor agonists

The bottom line

MEDVi delivers affordable compounded GLP-1s with a genuinely fast, low-friction path to treatment and clear pricing. Weigh that against a February 2026 FDA misbranding warning, reported AI-generated ads and testimonials (which MEDVi attributes to an affiliate), a data breach at its data partner OpenLoop affecting roughly 716,000 individuals (per the HHS breach portal and OpenLoop's own notice), and a model where clinical care and compounding are wholly outsourced. Speed-and-price seekers may find it a fit; anyone wanting an owned, tightly integrated clinical operation should look elsewhere.

Visit MEDVi

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

See how MEDVi ranks among GLP-1 providers

What changed & why

This brand's own history — every re-review and methodology recompute, logged. Rankings change when the evidence or the rules change, never for payment. See the site-wide methodology ledger for version history.

  1. Sep 14, 2026Methodologymethodology v65.425.36

    We changed how this score is calculated, and Weight Management / GLP-1 score moved from 5.42 to 5.36. 1 of the factors behind it moved. How we score.

    1 factor withdrawn — assessed coverage fell 12 → 11. Part of any score movement here reflects evidence we retracted, not a change in the brand.

  2. Aug 11, 2026Claim withdrawn6.205.42

    Weight Management / GLP-1 score moved from 6.20 to 5.42 after we withdrew 3 claims we could not source to a primary record. 6 of the factors behind it moved.

    3 factors withdrawn — assessed coverage fell 15 → 12. Part of any score movement here reflects evidence we retracted, not a change in the brand.

  3. Jul 24, 2026Re-review8.806.20

    Weight Management / GLP-1 score moved from 8.80 to 6.20 after a fresh review of the evidence. 15 of the factors behind it moved.

    Whether this score rests on more or less evidence than the previous one is not recorded — the earlier score did not store how many factors it assessed.

Frequently asked questions

Is MEDVi legit?

MEDVi is a real, high-revenue telehealth brand that uses licensed US physicians and a compounding partner (Belmar) whose accreditation we could not independently verify. That said, it operates as a marketing and care-coordination layer rather than a pharmacy itself, and it received a February 2026 FDA warning letter for misbranding. Reporting by Business Insider and Drug Discovery & Development has also described AI-generated fake ads, reviews and doctor testimonials tied to its marketing — which MEDVi attributes to an affiliate marketer it says it required to remove them — so weigh its claims carefully.

How much does MEDVi cost?

MEDVi does not publish pricing that we can retrieve, and we are not in a position to establish what it does publish: its site is refused on terms, so we do not render it. Figures that circulate — a discounted first month and a flat monthly refill rate — appear on affiliate pages that disclose commission and attribute the numbers to MEDVi rather than originating them, so we withdraw them rather than restate them. Treat any price you see quoted elsewhere as unverified, and confirm the current cost with MEDVi directly before you buy.

Can I cancel MEDVi and get a refund?

We cannot verify MEDVi's cancellation or refund terms. A 72-hour cancellation notice and a five-month refund conditioned on weight loss, less a 25% consultation fee, were previously shown here; their only sourcing was secondary, and medvi.org is refused on terms, so we cannot read the brand's own policy page to confirm or correct them. They are withdrawn rather than restated. Confirm cancellation and refund terms with MEDVi directly, in writing, before you buy.

Are MEDVi's medications FDA-approved?

No. MEDVi sells compounded semaglutide and tirzepatide, and compounded medications are not individually FDA-approved for safety, effectiveness or quality the way brand-name products are. A licensed clinician decides whether a compounded option is appropriate for you.

Is my data safe with MEDVi?

MEDVi routes patient data through its infrastructure partner OpenLoop, which disclosed a January 2026 data breach affecting roughly 716,000 individuals according to OpenLoop's own notice and the federal HHS breach portal (68,160 of them Texas residents; a hacker's forum claim of 1.6 million records is unverified). Because your information passes through that partner, this breach is a real consideration when deciding whether to enroll.

Work at MEDVi?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Scored on 11 of 14 factors · 3 sources cited

Regulatory

Other

What we couldn't verify

  • getmedvi.com could not be fetched directly (TLS cert expired); on-site pricing/eligibility corroborated via aggregators and medvi.io.
  • Trustpilot now verified at 4.4/14,176 (rendered fetch 2026-07-24); face value still discounted for documented AI/fake reviews.
  • Exact refill pricing for oral tablets and multi-month prepay tiers not consistently published.
  • Precise split of which pharmacy fills each product/format not clearly disclosed.
  • Withdrawn — MEDVi's prices ($179 first month / $299 monthly refills). MEDVi's prices ($179 first month / $299 monthly refills) are WITHDRAWN. The figures rested solely on weightlossproviderguide.com, which discloses that it "may earn a commission if you sign up through links on this page" and which states it took the figures from medvi.org. MEDVi's own pages render price as unfilled template variables (${seminject_sale_price}) and publish no dollar figure (glp1.medvi.org and home.medvi.org, both fetched 2026-08-10).
  • Withdrawn — MEDVi's cancellation terms (72-hour notice) and refund conditions (five months without weight loss, minus a 25% consultation fee). MEDVi's cancellation terms (72-hour notice) and refund conditions (five months without weight loss, minus a 25% consultation fee) are WITHDRAWN — affiliate-page sourcing only, and home.medvi.org publishes neither a cancellation window nor refund conditions (fetched 2026-08-10).
  • Withdrawn — MEDVi's states-served claim ("49 states, excludes North Dakota") and free-shipping claim. MEDVi's states-served claim ("49 states, excludes North Dakota") and free-shipping claim are WITHDRAWN — affiliate-only sourcing; neither home.medvi.org nor glp1.medvi.org states which states are served (fetched 2026-08-10).
  • Withdrawn — MEDVi's "$401 million in 2025 revenue, independently verified by The New York Times". MEDVi's "$401 million in 2025 revenue, independently verified by The New York Times" is WITHDRAWN. The only source was medicalfoundationofnc.org — which discloses affiliate commission, bylines its work to an unnamed "Editorial Team", and attributes the figure to the NYT WITHOUT naming or linking the article (fetched 2026-08-10). Neither we nor the intermediary retrieved the Times.
  • policy-clarity-fairness: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. MEDVi's home page LINKS a refund policy — so it does disclose, and the terms exist somewhere we did not reach. Every candidate URL we tried 404s. That is retrieval failure against a document the brand demonstrably publishes; scoring 30 for it would penalise MEDVi for a page we could not find.
  • access-speed: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. States-served is absent from the two pages we fetched, but we found no states or coverage page to check, and absence from a landing page is not absence from the site. Unclear → excluded, per the asymmetry rule.
  • popularity-momentum: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. The withdrawn item was a $401m revenue figure attributed to the NYT by an affiliate page that never linked the article. That is purely OUR sourcing failure, and no company is obliged to publish revenue — there is no disclosure to be absent. Marking MEDVi down 85→55 for it was the clearest instance of the defect this pass exists to undo.
  • Withdrawn — MEDVi advertising used fictitious personas, and that its founder acknowledged AI-generated website content,. The claim that MEDVi advertising used fictitious personas, and that its founder acknowledged AI-generated website content, is WITHDRAWN to gaps[]. It rested on a single trade-press investigation, which fails ORIGINATOR, and no primary record exists — attributing it ("Drug Discovery Trends reports…") is not sourcing. Withdrawn for want of a primary source, not disproved. (2026-08-11)
  • Withdrawn — MEDVi "owns no pharmacy, employs no physicians and holds no drug licenses". The claim that MEDVi "owns no pharmacy, employs no physicians and holds no drug licenses" is WITHDRAWN. One registry attempt was made on 2026-08-11 as ruled: NABP's accredited-pharmacy directory returned HTTP 403 to us, and openFDA's drugsfda endpoint is a record of drug approvals rather than pharmacy licensure, so a null result there is not evidence. Absence of a record in a registry we cannot query is not a record of absence — that is retrievalFailed, not an authoritative negative. Withdrawn, not disproved. (2026-08-11)
Last reviewed Sep 23, 2026 · methodology v6View the ledger

Top pick

MEDVi 5.36/10